Tocilizumab

Cross-source consensus on Tocilizumab from 2 sources and 6 claims.

2 sources · 6 claims

Uses

Tocilizumab inhibits interleukin-6 by binding the cytokine and preventing it from reaching its receptor, thereby blocking the downstream inflammatory cascade driving cytokine storm. — COVID-19 ICU Treatment Protocols: Medications, Prone Positioning, and Emerging Evidence
Tocilizumab is a monoclonal antibody that specifically inhibits the IL-6 receptor, targeting one key driver of cytokine storm rather than broadly suppressing all immune activity. — COVID-19 ICU Treatment: Clinical Updates and Protocols
Tocilizumab was reserved for patients with confirmed bilateral COVID-19 pneumonia who were deteriorating despite other treatments. — COVID-19 ICU Treatment Protocols: Medications, Prone Positioning, and Emerging Evidence
Whether combining dexamethasone and tocilizumab produces additive benefit without additive immunosuppressive risk requires formal RCT confirmation. — COVID-19 ICU Treatment: Clinical Updates and Protocols
Clinical evidence for tocilizumab in COVID-19 was emerging but not yet definitive at the time this session was recorded. — COVID-19 ICU Treatment Protocols: Medications, Prone Positioning, and Emerging Evidence
Preliminary non-peer-reviewed data from one hospital system reported 75–80% survival in mechanically ventilated patients treated with the combination of steroids plus tocilizumab. — COVID-19 ICU Treatment: Clinical Updates and Protocols